The antidepressant sertraline provides a novel host directed therapy module for augmenting TB therapy

  1. Deepthi Shankaran
  2. Anjali Singh
  3. Stanzin Dawa
  4. Prabhakar Arumugam
  5. Sheetal Gandotra
  6. Vivek Rao  Is a corresponding author
  1. Institute of Genomics and Integrative Biology, India

Abstract

A prolonged therapy, primarily responsible for development of drug resistance by Mycobacterium tuberculosis (Mtb), obligates any new TB regimen to not only reduce treatment duration but also escape pathogen resistance mechanisms. With the aim of harnessing the host response in providing support to existing regimens, we used sertraline (SRT) to stunt the pro-pathogenic type I IFN response of macrophages to infection. While SRT alone could only arrest bacterial growth, it effectively escalated the bactericidal activities of Isoniazid (H) and Rifampicin (R) in macrophages. This strengthening of antibiotic potencies by SRT was more evident in conditions of ineffective control by these frontline TB drug, against tolerant strains or dormant Mtb. SRT, could significantly combine with standard TB drugs to enhance early pathogen clearance from tissues of mice infected with either drug sensitive/ tolerant strains of Mtb. Further, we demonstrate an enhanced protection in acute TB infection of the highly susceptible C3HeB/FeJ mice with the combination therapy signifying the use of SRT as a potent adjunct to standard TB therapeutic regimens against bacterial populations of diverse physiology. This study advocates a novel host directed adjunct therapy regimen for TB with a clinically approved anti-depressant to achieve quicker and greater control of infection.

Data availability

This manuscript does not include any sequencing or high through put data. Also this work does not include any protein crystallization and diffraction analysis. The manuscript does not involve data for submission to depositing datasets into a domain-specific public archive.

Article and author information

Author details

  1. Deepthi Shankaran

    Cardio Respiratory Disease Unit, Institute of Genomics and Integrative Biology, New Delhi, India
    Competing interests
    The authors declare that no competing interests exist.
  2. Anjali Singh

    Cardio Respiratory Disease Unit, Institute of Genomics and Integrative Biology, New Delhi, India
    Competing interests
    The authors declare that no competing interests exist.
  3. Stanzin Dawa

    Cardio Respiratory Disease Unit, Institute of Genomics and Integrative Biology, New Delhi, India
    Competing interests
    The authors declare that no competing interests exist.
  4. Prabhakar Arumugam

    Cardio Respiratory Disease Unit, Institute of Genomics and Integrative Biology, New Delhi, India
    Competing interests
    The authors declare that no competing interests exist.
  5. Sheetal Gandotra

    Cardio Respiratory Disease Unit, Institute of Genomics and Integrative Biology, New Delhi, India
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1204-7290
  6. Vivek Rao

    Cardio Respiratory Disease Unit, Institute of Genomics and Integrative Biology, New Delhi, India
    For correspondence
    vivek.rao@igib.in
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8646-6634

Funding

Council of Scientific and Industrial Research, India (BSC0123)

  • Vivek Rao

Council of Scientific and Industrial Research, India (OLP0136)

  • Vivek Rao

Indian Council of Medical Research (GAP0213)

  • Vivek Rao

Council of Scientific and Industrial Research, India (STS0016)

  • Vivek Rao

Council of Scientific and Industrial Research, India (MLP2106)

  • Vivek Rao

Council of Scientific and Industrial Research, India (MLP2012)

  • Vivek Rao

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Bavesh D Kana, University of the Witwatersrand, South Africa

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations of the Control and Supervision of Experiments on Animals (CPCSEA). Experiments were conducted in line with approved protocols of the Institutional animal ethics committee, CSIR- IGIB (IGIB/IAEC/OCT2018/10, IGIB/IAEC/13/28/2020).

Human subjects: The study was conducted in strict accordance with recommendations of the National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, Indian Council of Medical Research (ICMR), Government of India. The protocols followed were approved by the Institutional human ethics committee of IGIB, proposal no 10, 2016 and Ref no: CSIR-IGIB/IHEC/2017-18 Dt. 08.02.2018. Patient informed consent was obtained prior to commencing the work.

Version history

  1. Preprint posted: May 28, 2020 (view preprint)
  2. Received: November 12, 2020
  3. Accepted: January 11, 2023
  4. Accepted Manuscript published: January 11, 2023 (version 1)
  5. Version of Record published: May 4, 2023 (version 2)

Copyright

© 2023, Shankaran et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,069
    views
  • 318
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Deepthi Shankaran
  2. Anjali Singh
  3. Stanzin Dawa
  4. Prabhakar Arumugam
  5. Sheetal Gandotra
  6. Vivek Rao
(2023)
The antidepressant sertraline provides a novel host directed therapy module for augmenting TB therapy
eLife 12:e64834.
https://doi.org/10.7554/eLife.64834

Share this article

https://doi.org/10.7554/eLife.64834

Further reading

    1. Microbiology and Infectious Disease
    Alejandro Prieto, Luïsa Miró ... Antonio Juarez
    Research Article

    Antimicrobial resistance (AMR) poses a significant threat to human health. Although vaccines have been developed to combat AMR, it has proven challenging to associate specific vaccine antigens with AMR. Bacterial plasmids play a crucial role in the transmission of AMR. Our recent research has identified a group of bacterial plasmids (specifically, IncHI plasmids) that encode large molecular mass proteins containing bacterial immunoglobulin-like domains. These proteins are found on the external surface of the bacterial cells, such as in the flagella or conjugative pili. In this study, we show that these proteins are antigenic and can protect mice from infection caused by an AMR Salmonella strain harboring one of these plasmids. Furthermore, we successfully generated nanobodies targeting these proteins, that were shown to interfere with the conjugative transfer of IncHI plasmids. Considering that these proteins are also encoded in other groups of plasmids, such as IncA/C and IncP2, targeting them could be a valuable strategy in combating AMR infections caused by bacteria harboring different groups of AMR plasmids. Since the selected antigens are directly linked to AMR itself, the protective effect extends beyond specific microorganisms to include all those carrying the corresponding resistance plasmids.

    1. Microbiology and Infectious Disease
    Hideo Fukuhara, Kohei Yumoto ... Katsumi Maenaka
    Research Article

    Canine distemper virus (CDV) belongs to morbillivirus, including measles virus (MeV) and rinderpest virus, which causes serious immunological and neurological disorders in carnivores, including dogs and rhesus monkeys, as recently reported, but their vaccines are highly effective. The attachment glycoprotein hemagglutinin (CDV-H) at the CDV surface utilizes signaling lymphocyte activation molecule (SLAM) and Nectin-4 (also called poliovirus-receptor-like-4; PVRL4) as entry receptors. Although fusion models have been proposed, the molecular mechanism of morbillivirus fusion entry is poorly understood. Here, we determined the crystal structure of the globular head domain of CDV-H vaccine strain at 3.2 Å resolution, revealing that CDV-H exhibits a highly tilted homodimeric form with a six-bladed β-propeller fold. While the predicted Nectin-4-binding site is well conserved with that of MeV-H, that of SLAM is similar but partially different, which is expected to contribute to host specificity. Five N-linked sugars covered a broad area of the CDV-H surface to expose receptor-binding sites only, supporting the effective production of neutralizing antibodies. These features are common to MeV-H, although the glycosylation sites are completely different. Furthermore, real-time observation using high-speed atomic force microscopy revealed highly mobile features of the CDV-H dimeric head via the connector region. These results suggest that sugar-shielded tilted homodimeric structure and dynamic conformational changes are common characteristics of morbilliviruses and ensure effective fusion entry and vaccination.